Phio Pharmaceuticals Corp
PHIO
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.27M
Close$
$3.51
251.4% upside
Current Fair Value
251.4% upsideUndervalued by 251.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.27 Million |
|---|---|
| Enterprise Value | $-5,762,267.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.45 |
| Beta | 0.81 |
| Outstanding Shares | 11,617,250 |
Return
| Return on Equity | -66.41% |
|---|---|
| Return on Assets | -62.78% |
| Return on Invested Capital | -28.25% |
Valuation & Multiples
| P/E Ratio | -0.68 |
|---|---|
| PEG | -0.54 |
| Price to Sales | - |
| Price to Book Ratio | 1.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.19 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.24
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.75%▼ 0.33% |
|---|---|
| Total Invested | $814,950▲ 113.16% |
| Investors Holding | 24▲ 7.00% |
ESG Score
No data
About Phio Pharmaceuticals Corp
10 employees
CEO: Gerrit Dispersyn Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-...